POSITION
Co-investor
BOARD
Observer
Thryv Therapeutics (Thryv) is a clinical-stage biotherapeutics company developing a first-in-class treatment for cardiovascular diseases. Thryv’s lead asset, LQT1213, is an SGK1 inhibitor being investigated in a Ph2a trial for genetic forms of Long QT Syndrome (LQTS). CTI Life Sciences Fund (CTI) was a new investor in this Series A extension and has a board observer position.